Ignite Creation Date:
2025-12-24 @ 12:45 PM
Ignite Modification Date:
2025-12-27 @ 4:07 PM
Study NCT ID:
NCT02510261
Status:
COMPLETED
Last Update Posted:
2023-12-06
First Post:
2015-07-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Sponsor:
Alnylam Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-07-16
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-11-23
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-16
First Submit QC Date:
None
Study First Post Date:
2015-07-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-11-16
Results First Submit QC Date:
None
Results First Post Date:
2023-12-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-05
Last Update Post Date:
2023-12-06
Last Update Post Date Type:
ACTUAL